LIXT (Lixte Biotechnology Holdings, Inc. Common Stock) Stock Analysis - News
Lixte Biotechnology Holdings, Inc. Common Stock (LIXT) is a publicly traded Healthcare sector company. As of May 21, 2026, LIXT trades at $5.60 with a market cap of $54.60M and a P/E ratio of 0.00. LIXT moved +1.90% today. Year to date, LIXT is +48.15%; over the trailing twelve months it is +327.48%. Its 52-week range spans $0.64 to $6.26. Rallies surfaces LIXT's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
What changed in LIXT news today?
LIXTE Files Q1 10-Q, Expands Ovarian Cancer Study with GSK’s Dostarlimab: LIXTE filed its Q1 2026 Form 10-Q detailing advances in its lead compound LB-100, which showed a favorable safety profile in combination with GSK’s dostarlimab and prompted expansion of its ovarian cancer trial. The company also integrated Liora Technologies Europe and advanced its LIGHT proton therapy platform.
Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
van der Baan Bastiaan Jeroen bought 10.00K (~$28.00K) on Oct 3, 2023.
Bernards Rene bought 5.53K (~$13.87K) on Oct 3, 2023.
LIXT Analyst Consensus
LIXT analyst coverage data. Average price target: $0.00.
Common questions about LIXT
What changed in LIXT news today?
LIXTE Files Q1 10-Q, Expands Ovarian Cancer Study with GSK’s Dostarlimab: LIXTE filed its Q1 2026 Form 10-Q detailing advances in its lead compound LB-100, which showed a favorable safety profile in combination with GSK’s dostarlimab and prompted expansion of its ovarian cancer trial. The company also integrated Liora Technologies Europe and advanced its LIGHT proton therapy platform.
Does Rallies summarize LIXT news?
Yes. Rallies summarizes LIXT news with ticker-specific context, catalysts, source links, and AI-generated market summaries when news is available.
Is LIXT research on Rallies investment advice?
No. Rallies provides research, data, and educational context for LIXT. It does not provide personalized investment advice.
